Circulating Soluble Suppression of Tumorigenicity 2 Predicts Recurrence After Radiofrequency Ablation of Persistent Atrial Fibrillation

• DOI: 10.3389/fcvm.2021.653312
• Publication Date: 2021-06-17T04:54:32Z
• Authors: Ruopeng Tan; Haixu Yu; Xu Han; Yang Liu; Xiaolei Yang; Yun-Long Xia; Xiaomeng Yin
• Keywords: recurrence; Hazard ratio; Immunology; Cardiology; Receiver operating characteristic; Heart failure; Cardiovascular Medicine; Ablation; Proportional hazards model; Biochemistry; 03 medical and health sciences; 0302 clinical medicine; Health Sciences; Diseases of the circulatory (Cardiovascular) system; atrial fibrillation; Internal medicine; sST2; Immunology and Microbiology; FOS: Clinical medicine; Confidence interval; Radiofrequency ablation; Life Sciences; Biomarker; Innate Lymphoid Cells in Immunity; Atrial fibrillation; 3. Good health; Chemistry; RC666-701; atrial fibrosis; biomarker; Medicine; Surgery; Catheter ablation; Type 2 Immunity; Diagnosis and Management of Eosinophilic Esophagitis

Objective: A more extensively fibrotic left atrium contributes to atrial fibrillation (AF) occurrence, persistence, and recurrence. The soluble suppression of tumorigenicity 2 (sST2) has emerged as a ventricular biomarker for patients with heart failure. present study is investigate associations between circulating sST2 risk recurrence after ablation in AF patients. Methods: We measured the baseline plasma level from persistent ( n = 117) paroxysmal 93) Patients were followed up 15 months ablation. relationship was assessed by multivariable Cox regression. cutoff value determined receiver operating characteristic curve. volume index (LAVI) multivariate linear regression analysis. Serial measurements also conducted 24 h, 6 months, ST2 localization examined appendages immunohistochemistry Western blot. Results: Baseline positively associated LAVI group, elevated (≥39.25 ng/ml) independently increased (area under curve 0.748), hazard ratio 1.038 (95% confidence interval 1.017–1.060, P < 0.001) when adjusted co-variables. In contrast, cannot predict AF. Conclusions: patients, serves marker radiofrequency ≥ 39.25 ng/ml are likely develop within year.